|
57 Products |
| 57 Products |
|
190 Diseases |  |
11232 News |  |
| «12...9899100101102103104105106107108109110 |
- ||| Mayzent (siponimod) / Novartis
Enrollment closed: Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Nov 22, 2011
P2, N=186, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Enrolling by invitation --> Active, not recruiting
- ||||||| Trial completion: FREEDOMS II: Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Nov 22, 2011
P3, N=632, Completed, Sponsor: Novartis Pharmaceuticals
Enrolling by invitation --> Active, not recruiting Enrolling by invitation --> Completed
- ||||| Enrollment change: Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Nov 15, 2011
P3, N=920, Completed, Sponsor: Novartis
Enrolling by invitation --> Completed N=1250 --> 920
- ||||||| Trial completion: Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Nov 15, 2011
P3, N=920, Completed, Sponsor: Novartis
N=1250 --> 920 Active, not recruiting --> Completed
- | GSK 2018682 / GSK
New P1 trial: A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers. (clinicaltrials.gov) - Nov 2, 2011
P1, N=16, Completed, Sponsor: GlaxoSmithKline
- fingolimod / Generic mfg.
Enrollment open: The Gilenya Pregnancy Registry (clinicaltrials.gov) - Oct 10, 2011
P=N/A, N=500, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||| fingolimod / Generic mfg.
Clinical: PASSAGE: Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies (clinicaltrials.gov) - Sep 26, 2011
P=N/A, N=3600, Recruiting, Sponsor: Novartis
- ||||| New P4 trial: Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression (clinicaltrials.gov) - Sep 18, 2011
P4, N=54, Completed, Sponsor: Novartis Pharmaceuticals
- ||||||| Trial completion: FREEDOMS II: Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Sep 6, 2011
P3, N=1083, Completed, Sponsor: Novartis
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||| Ponvory (ponesimod) / J&J
Trial completion: Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Aug 18, 2011
P2, N=464, Completed, Sponsor: Actelion
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| New P4 trial: Fingolimod -Response According to Coping - Evaluation (clinicaltrials.gov) - Aug 17, 2011
P4, N=189, Completed, Sponsor: Novartis Pharmaceuticals
- LX 2931 / Lexicon Pharma
New P1 trial: A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid Arthritis (clinicaltrials.gov) - Aug 14, 2011
P1, N=10, Completed, Sponsor: Lexicon Pharmaceuticals
- | GSK 2018682 / GSK
New P1 trial: Assessment of Repeat Ascending Doses of GSK2018682 in Healthy Volunteers (clinicaltrials.gov) - Aug 10, 2011
P1, N=40, Completed, Sponsor: GlaxoSmithKline
- ||||| iSONEP (sonepcizumab) / Pfizer, Apollo Endosurgery
New P2 trial, Monotherapy: Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD (clinicaltrials.gov) - Aug 9, 2011
P2, N=160, Recruiting, Sponsor: Lpath, Inc.